SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed. The company is developing an injectable biodegradable hydrogel that enables extended, localized release of cancer immunotherapy at the site of surgical tumor resection to improve patient survival outcomes. SURGE is based in Cambridge, MA.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/17/22 | $26,000,000 | Series A |
8VC Alumni Ventures Group Camford Capital Cancer Research Institute. Intuitive Venture Partners Khosla Ventures Pitango HealthTech | undisclosed |
| 07/20/23 | $32,000,000 | Series B |
8VC Alumni Ventures Group Bioluminescence Ventures  Camford Capital Cancer Research Institute. Intuitive Venture Partners KdT Ventures Khosla Ventures Piedmont Capital Investments Pitango HealthTech | undisclosed |
